Scholarlink

<p>Peroxidasin (PXDN) is a multi-domain heme peroxidase that catalyzes sulfilimine cross-links in type IV collagen, a reaction essential for basement membrane stability. In addition to its structural role, PXDN has been implicated in oxidative stress regulation, fibrosis, and tumorigenesis. Antibody-based detection is critical for defining PXDN expression and localization, yet few commercial reagents have been rigorously validated, limiting reproducibility. Here, we assessed the specificity and performance of a commercially available anti-PXDN antibody (Abbexa, abx101906) in immunohistochemistry and immunocytochemistry applications. Validation was performed in formalin-fixed, paraffin-embedded human kidney tissue and in a primary kidney fibroblast line under <i>PXDN</i> silencing and overexpression conditions. The antibody yielded reproducible labeling patterns and demonstrated specificity across cellular contexts. These findings establish abx101906 as a reliable tool for immunofluorescence-based detection of PXDN. This validation provides a foundation for future studies of PXDN biology in kidney development, disease, and potential therapeutic targeting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Validation and performance assessment of a commercial anti-peroxidasin antibody

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Isabel Brandão,
  • Roberto Silva,
  • Bárbara Gomes,
  • Jorge R. Almeida,
  • João Paulo Oliveira,
  • Inês S. Alencastre

摘要

Peroxidasin (PXDN) is a multi-domain heme peroxidase that catalyzes sulfilimine cross-links in type IV collagen, a reaction essential for basement membrane stability. In addition to its structural role, PXDN has been implicated in oxidative stress regulation, fibrosis, and tumorigenesis. Antibody-based detection is critical for defining PXDN expression and localization, yet few commercial reagents have been rigorously validated, limiting reproducibility. Here, we assessed the specificity and performance of a commercially available anti-PXDN antibody (Abbexa, abx101906) in immunohistochemistry and immunocytochemistry applications. Validation was performed in formalin-fixed, paraffin-embedded human kidney tissue and in a primary kidney fibroblast line under PXDN silencing and overexpression conditions. The antibody yielded reproducible labeling patterns and demonstrated specificity across cellular contexts. These findings establish abx101906 as a reliable tool for immunofluorescence-based detection of PXDN. This validation provides a foundation for future studies of PXDN biology in kidney development, disease, and potential therapeutic targeting.